AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million
FibroGen Inc. FGEN stock is trading higher on Thursday. The company announced the sale of its China subsidiary to AstraZeneca Plc AZN for approximately $160 million.
AstraZeneca Rises Almost 9% in a Month: How to Play the Stock
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.
AstraZeneca Post 2024 Earnings: Unwanted Headwinds Warrant Downgrade To Hold
AstraZeneca PLC beat Q4 and full-year 2024 earnings estimates, with significant revenue and EPS growth, and forecasts further growth in 2025 despite China-related setbacks. The company faces challenges, including new drug data disappointments and a China probe, impacting stock performance and raising concerns about management and future growth. AstraZeneca's oncology division remains strong, but patent expiries and mixed clinical trial results create uncertainties about achieving long-term revenue targets across all divisions.
What's a Good Price for AstraZeneca Stock?
Healthcare companies are interesting because they are not highly correlated with macroeconomic factors.
2 Healthcare Stocks That Tumbled in 2024
Vertex Pharmaceuticals (VRTX -0.77%) and AstraZeneca (AZN -1.17%), two of the world's leading drugmakers, missed last year's strong market rally. Both finished 2024 slightly in the red.
AstraZeneca's £2.8bn shot following upgrade
AstraZeneca PLC (LSE:AZN) shares climbed 1.6% in early trading, adding £2.9 billion to the company's market value after UBS upgraded its rating to 'buy' from 'neutral'. The investment bank raised its price target from £115 to £142, citing AZ's strong drug pipeline and long-term growth potential.
AstraZeneca gets the seal of approval from leading US investment bank - here's why
Morgan Stanley has initiated coverage of AstraZeneca PLC (LSE:AZN) with an ‘overweight' rating, highlighting the pharmaceutical giant's current share price as a "compelling entry point" ahead of key developments in its drug pipeline. In a research note published on Wednesday, the bank set a price target of 14,500p, with potential upside depending on the success of upcoming clinical trial results.
Why AstraZeneca Topped the Market on Thursday
A fresh earnings release was the news development powering AstraZeneca's (AZN 2.01%) share price higher on Thursday. Investors were clearly impressed by the pharmaceutical company's numbers, as the stock closed the day more than 2% higher in value.
AZN Q4 Earnings Lag, Sales Beat, Stock Up on China Probe Update
AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business impact of the Chinese investigations remains minor.
AstraZeneca PLC (AZN) Q4 2024 Earnings Call Transcript
AstraZeneca PLC (NASDAQ:AZN ) Q4 2024 Earnings Conference Call February 6, 2025 6:00 AM ET Company Participants Pascal Soriot – Executive Director and Chief Executive Officer Iskra Reic – Executive Vice President-International Aradhana Sarin – Executive Director and Chief Financial Officer Dave Fredrickson – Executive Vice-President-Oncology Business Unit Susan Galbraith – Executive Vice President-Oncology R&D Ruud Dobber – Executive Vice President-BioPharmaceuticals Business Unit Sharon Barr – Executive Vice President-BioPharmaceuticals R&D Marc Dunoyer – Chief Executive Officer-Alexion Conference Call Participants James Gordon – JPMorgan Luisa Hector – Berenberg Jo Walton – UBS Sachin Jain – Bank of America Mattias Sigmund – Handelsbanken Richard Parks – BNP Paribas Exane Steve Scala – TD Cowen Emily Field – Barclays Simon Baker – Redburn Atlantic Eric Le Berrigaud – Stifel Justin Smith – Bernstein Rajan Sharma – Goldman Sachs Gonzalo Artiach – Danske Bank Pascal Soriot Thank you, Andy. Welcome everybody.
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Astrazeneca (AZN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Astrazeneca (AZN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
